Showing results (301-310 of 318) with videos related to
Sort By:
Pageof 32
Journal of Medicinal Chemistry|February 12, 2008
3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinasesZhiqin Ji, Asma A Ahmed, Daniel H Albert, et al.Frontiers in Oncology|September 5, 2019
Trends of Postoperative Radiotherapy for Completely Resected Non-small Cell Lung Cancer in China: A Hospital-Based Multicenter 10-Year (2005-2014) Retrospective Clinical Epidemiological StudyYu Men, Le Wang, Ye Zhang, et al.Bioorganic & Medicinal Chemistry Letters|September 3, 2003
Alpha-keto amides as inhibitors of histone deacetylaseCarol K Wada, Robin R Frey, Zhiqin Ji, et al.Thoracic Cancer|May 31, 2019
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang, Xia Song, Yuhui Zhang, et al.Thoracic Cancer|September 26, 2018
Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional studyYing Cheng, Yan Wang, Jun Zhao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2021
A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II StudyQing Zhou, Lin Wu, Pei Hu, et al.The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.Blood|January 9, 2007
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemiaDeepa B Shankar, Junling Li, Paul Tapang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.Thoracic Cancer|December 22, 2021
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in ChinaYuequan Shi, Jian Fang, Chengzhi Zhou, et al.Pageof 32